Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AC 102

Drug Profile

AC 102

Alternative Names: AC-102

Latest Information Update: 03 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AudioCure Pharma
  • Developer AudioCure Pharma; Radboud University Nijmegen Medical Centre
  • Class Anti-inflammatories; Carbolines; Small molecules
  • Mechanism of Action Antioxidants; Apoptosis inhibitors; Brain-derived neurotrophic factor expression stimulants; Inflammation mediator modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sensorineural hearing loss
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Sensorineural hearing loss
  • No development reported Hearing loss

Most Recent Events

  • 01 Apr 2024 Pharmacodynamics data from preclinical trial in Hearing loss released by AudioCure Pharma
  • 28 Dec 2023 No recent reports of development identified for phase-I development in Hearing loss(In volunteers) in Netherlands (Intratympanic, Suspension)
  • 10 Mar 2022 Phase-II clinical trials in Sensorineural hearing loss (In the elderly, In adults) in Germany, Czech Republic, Austria (Intratympanic) (EudraCT2021-004323-33)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top